Related Experiment Videos
[The subrenal capsule assay modified with three-dimensional measurement (volume method) and its higher predictivity]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 1, 1987
Summary
This study enhances the Subrenal Capsule Assay (SRCA) for predicting anticancer drug effectiveness. Modified SRCA using 3D tumor volume measurements improves accuracy and clinical relevance for various cancers.
Area of Science:
- Oncology
- Experimental Therapeutics
- Preclinical Cancer Models
Background:
- The Subrenal Capsule Assay (SRCA) is an in vivo method for evaluating anticancer agent sensitivity.
- A key limitation of SRCA is host reaction interference around day 6, prompting research into modifications.
- Immunosuppression and improved measurement techniques are explored to enhance SRCA reliability.
Purpose of the Study:
- To refine the SRCA by incorporating three-dimensional tumor volume measurements to minimize host reaction misinterpretations.
- To prospectively evaluate the modified SRCA's accuracy and clinical utility in diverse malignancies.
- To compare the performance of the modified SRCA against the original mean diameter measurement method.
Main Methods:
- Implemented a three-dimensional volume measurement technique for tumor grafts in the SRCA, replacing the original mean diameter method.
- Conducted 16 assays across 15 cases of miscellaneous malignancies.
- Performed prospective quantitative analysis correlating assay predictions with clinical outcomes.
Main Results:
- Achieved 94% evaluability across the assays.
- Demonstrated a predictive accuracy of 77% for 22 treatments.
- Observed an improved assay/clinical correlation coefficient of 0.38 and a coincidence of ranking order of 6/6, compared to the original method's 0.00 and 1/3.
- 9 out of 15 patients achieved a clinical response of more than Partial Response (PR).
- Two patients maintained a Complete Response (CR) for two years with assay-guided single-agent treatments.
Conclusions:
- The modified SRCA, utilizing 3D volume measurements, offers improved evaluability and predictive accuracy for anticancer agents.
- This enhanced SRCA demonstrates greater utility and better correlation with clinical responses compared to the original method.
- The modified SRCA shows promise as a valuable tool for guiding individualized cancer treatment strategies.